A better understanding of the roles of the adaptive and innate immune systems in the
oncogenesis of cancers including multiple myeloma (MM) has led to the development of …

Despite documented evidence that ovarian cancer cells express immune-checkpoint
molecules, such as PD-1 and PD-L1, and of a positive correlation between the presence of …

Chimeric antigen receptor (CAR) T cell therapy, which targets tumors with high specificity
through the recognition of particular antigens, has emerged as one of the most rapidly …

Mutant KRAS promotes the proliferation, metastasis, and aggressiveness of various cancers
including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) …

Chimeric Antigen Receptor T-cell (CAR-T) therapies are transforming the treatment of B-cell
lymphoproliferative disorders and multiple myeloma, yet global access challenges and …

Chimeric antigen receptor T-cell (CAR-T) therapy has ushered in a new era for the treatment
of multiple myeloma (MM). Numerous clinical studies, especially those involving B-cell …

The basic idea of modulating the immune system to better recognize and fight tumor cells
has led to the successful introduction of adoptive cellular immunotherapy (ACT). ACT-based …

Multiple myeloma (MM) treatment remains challenging due to its relapsed/refractory disease
course as well as intra-and inter-patient heterogeneity. Cellular immunotherapies, especially …

Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of
relapsed/refractory multiple myeloma. The current Food and Drug Administration approved …

Multiple myeloma (MM), characterized by abnormal proliferation of clonal plasma cells, is an
incurable hematological malignancy. Various immunotherapy strategies have emerged as …